On May 14, 2019, Sun, Changan; Gao, Peng; Liu, Lei; Bao, Rudi published a patent.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol The title of the patent was Pharmaceutical composition containing fibroblast growth factor receptor 4 (FGFR4) inhibitor. And the patent contained the following:
The invention relates to a pharmaceutical composition containing a fibroblast growth factor receptor 4 (FGFR4) inhibitor, and in particular to a pharmaceutical composition containing a FGFR4 inhibitor having structure of formula (I). The pharmaceutical composition has high inhibiting effect on activity of FGFR4 kinase, and can be widely applied to preparation of pharmaceuticals for treating cancers, especially liver cancer, gastric cancer, prostatic cancer, skin cancer, ovarian cancer, lung cancer, breast cancer, colon cancer, pancreatic cancer, esophageal cancer, glioma or rhabdomyosarcoma. The experimental process involved the reaction of 1-[(Dibenzylamino)methyl]cyclopropanol(cas: 428855-17-8).Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol
The Article related to fibroblast growth factor receptor inhibitor antineoplastic cancer, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-[(Dibenzylamino)methyl]cyclopropanol
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts